Paclitaxel

製品コードS1150 別名:NSC 125973

Paclitaxel化学構造

分子量(MW):853.91

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

サイズ 価格(税別)  
JPY 15106.00
JPY 11620.00
JPY 44820.00

カスタマーフィードバック(4)

  • Characterization of nuclear damage by PARP as DNA damage repair marker. CLSM images of dual drug conjugated nanoparticle treatments to HeLa cells for 24 h at their respective IC50 drug dosages compared to nontreated control. Cells were stained with PARP-Alexafluor 488 antibody (green).

    ACS Appl Mater Interfaces, 2015, 7(14): 7584-98. Paclitaxel purchased from Selleck.

    Microscope image (406) magnification of U937 cells after exposure to SM-TNs. a) Untreated U937 cells. b) U937 cells treated with 200 nM, and 35 nM ODS empty shells. c) U937 cells treated with microcrystalline (free) Taxol prepared by sonicating Taxol in 20%H3PO4/0.8% SDS solution. d) U937 cells treated with 200 nM SM-TN. A SM-TN is seen in the middle of the picture. e) U937 cells treated with 35 nM SMTN.The nanowires are too small to see at this magnification, but their effect on the cells is clearly visible. Scale bar = 10 mm.

    RSC Adv 2011 1, 884-892. Paclitaxel purchased from Selleck.

  • Inhibitory effect of lenvatinib and paclitaxel on the proliferation of ATC cells. Cells were treated with the indicated concentrations of lenvatinib (A) and paclitaxel (B) for 48 h, followed by MTT assay to evaluate cell proliferation. IC50 values of these two drugs for each cell line were calculated using the Reed-Muench method

    Am J Cancer Res, 2017, 7(4):903-912. Paclitaxel purchased from Selleck.

    Western blot analysis of pPRAS40 (T246), pS6 (S240/S244), and pS6 (S235/S236) proteins in (A) HeyA8 cells and (B) SKOV3 cells treated with 0.37 μM or 10 μM paclitaxel in three-dimensional cell culture for 24 hours.

    PLoS One, 2016, 11(5):e0155052. . Paclitaxel purchased from Selleck.

製品安全説明書

Microtubule Associated阻害剤の選択性比較

生物活性

製品説明 Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.
ターゲット
Microtubule (human endothelial cells) [1]
0.1 pM
体外試験

Paclitaxel inhibits non-endothelial type human cells at 104 - to 105 -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. [1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. [2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
TE-15 NIXrVFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTBwMECwNlg4KM7:TR?= M{TnRnNCVkeHUh?=
LC-2-ad M1G0emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIn4dlhKSzVyPUCuNFAxOzF5IN88US=> M3H4dHNCVkeHUh?=
RL95-2 NHv1XJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTBwMECwOlY5KM7:TR?= MlHRV2FPT0WU
MZ1-PC NWnyOFRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTsd49KSzVyPUCuNFAxPzJ7IN88US=> MkjJV2FPT0WU
TE-8 MmfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{n4TmlEPTB;MD6wNFEyPyEQvF2= MV\TRW5ITVJ?
SW954 M1PKVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVW4RZJXUUN3ME2wMlAxOTF7IN88US=> MYDTRW5ITVJ?
TE-11 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HIPGlEPTB;MD6wNFEzOyEQvF2= MkTUV2FPT0WU
PSN1 NYDsV2NOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjHTWM2OD1yLkCwNVMh|ryP NHvyZWZUSU6JRWK=
MOLT-4 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnMXJVrUUN3ME2wMlAxOTR7IN88US=> NXjPcJlzW0GQR1XS
697 NH\nTZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4G4cGlEPTB;MD6wNFE2KM7:TR?= M1zDV3NCVkeHUh?=
ETK-1 NGrDbZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXlTXd6UUN3ME2wMlAxOTV{IN88US=> NV35TGNiW0GQR1XS
TE-10 MlO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;TemlEPTB;MD6wNFE2PCEQvF2= MmX5V2FPT0WU
HUTU-80 NVvJPWRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHa[JhKSzVyPUCuNFAyPjhizszN NX\XdFN1W0GQR1XS
NTERA-S-cl-D1 NFHvVnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTvTWM2OD1yLkCwNlA6KM7:TR?= MV\TRW5ITVJ?
MFH-ino M4\qN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX22TlZQUUN3ME2wMlAxOjZ6IN88US=> NEXvc5RUSU6JRWK=
IA-LM NXL4T49pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlyxTWM2OD1yLkCwNlgh|ryP MVPTRW5ITVJ?
MC116 MlzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLsTWM2OD1yLkCwNlg6KM7:TR?= NX;FTG5uW0GQR1XS
RKO NXfXTlI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYezeJRVUUN3ME2wMlAxOjl6IN88US=> NXXWTXRzW0GQR1XS
MRK-nu-1 M3;ReGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTBwMECyPVkh|ryP NVf0[4RQW0GQR1XS
VA-ES-BJ NVrRbmtbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rkOGlEPTB;MD6wNFMh|ryP MX7TRW5ITVJ?
KALS-1 MmP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\pTWM2OD1yLkCwN|A5KM7:TR?= M1XZdnNCVkeHUh?=
BB30-HNC NHmwfmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlj2TWM2OD1yLkCwN|E1KM7:TR?= Mlz5V2FPT0WU
ACN Mk[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTBwMECzNVYh|ryP MVfTRW5ITVJ?
TE-9 NUGzem95T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIOzXVVKSzVyPUCuNFA{OjZizszN MkPaV2FPT0WU
SIG-M5 MlrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4m3ZmlEPTB;MD6wNFMzPyEQvF2= M3PITHNCVkeHUh?=
no-10 NXv0WHJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXuTWM2OD1yLkCwN|YzKM7:TR?= M3S0fnNCVkeHUh?=
EW-1 NEjVfXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXsTWM2OD1yLkCwN|cyKM7:TR?= MmO3V2FPT0WU
SK-LMS-1 MlXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTBwMEC0NFEh|ryP NXLydGxrW0GQR1XS
GT3TKB NXzD[5RsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLYTWM2OD1yLkCwOFM1KM7:TR?= NWLBVG5SW0GQR1XS
ES4 Mnj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDGTWM2OD1yLkCwOFQ6KM7:TR?= MnLnV2FPT0WU
IMR-5 NXfLVItCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mme2TWM2OD1yLkCwOFUh|ryP MmrGV2FPT0WU
NCI-H1648 NHHy[nBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nHSmlEPTB;MD6wNFQ3QSEQvF2= M36zTHNCVkeHUh?=
MV-4-11 NH7nd3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfHcVd1UUN3ME2wMlAxPDd3IN88US=> MWLTRW5ITVJ?
SK-UT-1 MlL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjHTWM2OD1yLkCwOFgh|ryP M{nITHNCVkeHUh?=
NB13 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnXdpNnUUN3ME2wMlAxPDlzIN88US=> M1HhNnNCVkeHUh?=
DJM-1 NGrub|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\DfW5GUUN3ME2wMlAxPTNizszN NVu2N2hxW0GQR1XS
ES8 MmnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\SelZKSzVyPUCuNFA2OzhizszN NEXQZ3ZUSU6JRWK=
TE-6 MmnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\6TWM2OD1yLkCwOVch|ryP NWnvW2xmW0GQR1XS
KS-1 NYC1TZluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzWUZBFUUN3ME2wMlAxPTh{IN88US=> MnrlV2FPT0WU
TE-1 M3vrXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPBTZdPUUN3ME2wMlAxPjB4IN88US=> M1XnSHNCVkeHUh?=
ATN-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTBwMEC2NFkh|ryP NU\BeVJzW0GQR1XS
A4-Fuk MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HlbmlEPTB;MD6wNFYyOSEQvF2= NXrCWZNNW0GQR1XS
ALL-PO M3SzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTBwMEC2N{DPxE1? NHLGUHhUSU6JRWK=
BE-13 MmXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTBwMEC2N|Yh|ryP M4Pt[HNCVkeHUh?=
KM12 M3fEZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M374cmlEPTB;MD6wNFY{PyEQvF2= MnK2V2FPT0WU
NOS-1 MmDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTBwMEC2OUDPxE1? NV7BWmlNW0GQR1XS
SW962 NYi1UYF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTBwMEC2OlIh|ryP M2TRPHNCVkeHUh?=
OCUB-M M4HnSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjBXYJKSzVyPUCuNFA3PjJizszN NVGyRVF1W0GQR1XS
NCI-H510A MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jzemlEPTB;MD6wNFY3PSEQvF2= MoHXV2FPT0WU
EW-16 NWrMbJdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13STWlEPTB;MD6wNFY6PCEQvF2= MlG5V2FPT0WU
KGN NXLWS4pPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnicpRPUUN3ME2wMlAxPzF{IN88US=> M2XzUnNCVkeHUh?=
LS-411N MmTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;JTWM2OD1yLkCwO|E4KM7:TR?= NHPt[GFUSU6JRWK=
Becker NYW4d3pqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTBwMEC3NkDPxE1? MnPKV2FPT0WU
HC-1 MlHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2H6Z2lEPTB;MD6wNFczOSEQvF2= NUTF[2NuW0GQR1XS
CESS NG\GNmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknTTWM2OD1yLkCwO|M4KM7:TR?= NE\vVIRUSU6JRWK=
KURAMOCHI M3zPNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTBwMEC3OFgh|ryP MYfTRW5ITVJ?
TGBC24TKB NVTCRVhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTBwMEC3OVIh|ryP NH7XfmxUSU6JRWK=
SW982 NFHEWJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInM[mdKSzVyPUCuNFA4PjZizszN NUTmco84W0GQR1XS
HCE-4 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnwTWM2OD1yLkCwO|Y4KM7:TR?= MWjTRW5ITVJ?
LOUCY NX;pSZYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37WRmlEPTB;MD6wNFc4PSEQvF2= NXHUcXJrW0GQR1XS
8-MG-BA MlLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVryO2lqUUN3ME2wMlAxPzl4IN88US=> MVXTRW5ITVJ?
HT-144 NXfic40yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF64VWZKSzVyPUCuNFA5KM7:TR?= MlnhV2FPT0WU
LXF-289 Mn[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HjUWlEPTB;MD6wNFgyQCEQvF2= Ml\TV2FPT0WU
RS4-11 M3i0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HiU2lEPTB;MD6wNFg{PiEQvF2= MkHMV2FPT0WU
DEL NI\5dnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrFZmtKSzVyPUCuNFA5PDVizszN M1G3eXNCVkeHUh?=
OCI-AML2 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV[1XmlsUUN3ME2wMlAxQDV{IN88US=> NX7SRXk2W0GQR1XS
CCRF-CEM NV76Z5dsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7qTWM2OD1yLkCwPFcyKM7:TR?= M1fnWXNCVkeHUh?=
A388 Ml7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHrVZNKSzVyPUCuNFA5PzRizszN MXzTRW5ITVJ?
KNS-42 MlzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vPb2lEPTB;MD6wNFg6OSEQvF2= MmLGV2FPT0WU
OVCAR-4 M2rENGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXO2eJJvUUN3ME2wMlAxQTB2IN88US=> NVzOcYRVW0GQR1XS
NCI-H1355 NWrJe285T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zPZWlEPTB;MD6wNFkyPCEQvF2= Mn33V2FPT0WU
BL-70 NV;PPFhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYD0dFdoUUN3ME2wMlAxQTNizszN M1fzOHNCVkeHUh?=
BL-41 NX7qdXBOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTBwMEC5N|Qh|ryP NHLXVotUSU6JRWK=
A101D NWLBc3hzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTJe|FbUUN3ME2wMlAxQTZizszN NUnLeos2W0GQR1XS
HL-60 MmqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfjTWM2OD1yLkCwPVY3KM7:TR?= NUjGcJdHW0GQR1XS
COR-L279 NWmweWNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPKd2ptUUN3ME2wMlAxQTl7IN88US=> M1XGV3NCVkeHUh?=
NCI-SNU-16 M{DUWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXSVItKSzVyPUCuNFExODhizszN NHvpSVdUSU6JRWK=
Calu-6 MmS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfyTWM2OD1yLkCxNFEzKM7:TR?= Ml;2V2FPT0WU
SR MkLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTJPFFuUUN3ME2wMlAyODJ4IN88US=> MYPTRW5ITVJ?
QIMR-WIL M322fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmWzTWM2OD1yLkCxNFM{KM7:TR?= M3ns[nNCVkeHUh?=
LB647-SCLC MoKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TEWWlEPTB;MD6wNVA2OSEQvF2= NGDFPYNUSU6JRWK=
RPMI-8226 NXq0XHVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\DTWM2OD1yLkCxNVAzKM7:TR?= MWXTRW5ITVJ?
SK-PN-DW NUTrTFg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17Ze2lEPTB;MD6wNVEyOiEQvF2= NWXac3RQW0GQR1XS
SF268 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3XTnl2UUN3ME2wMlAyOTVzIN88US=> NYnMeYZbW0GQR1XS
HD-MY-Z MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjFRnJQUUN3ME2wMlAyOTZ|IN88US=> MXrTRW5ITVJ?
DOHH-2 M{fwSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXJeWRKSzVyPUCuNFEzODNizszN NFvuN2tUSU6JRWK=
SCC-3 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWflO3N{UUN3ME2wMlAyOjB2IN88US=> M1z0Z3NCVkeHUh?=
ST486 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jmNmlEPTB;MD6wNVIxPCEQvF2= M{nJS3NCVkeHUh?=
NALM-6 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTBwMEGyNVQh|ryP MX\TRW5ITVJ?
NCI-H1436 NWnRNmdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLRSpJuUUN3ME2wMlAyOjNzIN88US=> NXT3OFczW0GQR1XS
KE-37 NXvpfItkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4iwcmlEPTB;MD6wNVI{PCEQvF2= M2TFTXNCVkeHUh?=
RPMI-8402 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7IdZBZUUN3ME2wMlAyOjV4IN88US=> NFfJcFhUSU6JRWK=
RXF393 M4fpWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTBwMEGyOVch|ryP NEjxWFNUSU6JRWK=
KARPAS-45 NEfXUJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTBwMEGyO{DPxE1? NHq3d5JUSU6JRWK=
HOP-62 M1X5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mor0TWM2OD1yLkCxNlc3KM7:TR?= MX\TRW5ITVJ?
ES1 NHT5clFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFj2[XZKSzVyPUCuNFEzQDhizszN NXT4cGZPW0GQR1XS
L-363 MoTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTBwMEGzOVEh|ryP MmP4V2FPT0WU
GI-1 NHjNSXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEKxNYRKSzVyPUCuNFE{PzNizszN MkD6V2FPT0WU
CTV-1 NYXEXnZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3GxXmlEPTB;MD6wNVQ4QCEQvF2= NHrCUm9USU6JRWK=
TE-5 MkixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rQUGlEPTB;MD6wNVQ6PiEQvF2= Mnv0V2FPT0WU
SNU-C2B Mme5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzzdGc6UUN3ME2wMlAyPDl4IN88US=> M4G2e3NCVkeHUh?=
K-562 NFzaZXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoK2TWM2OD1yLkCxOVE3KM7:TR?= MUXTRW5ITVJ?
SNB75 NYrtR5JpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDmTWM2OD1yLkCxOVQh|ryP M2LqSHNCVkeHUh?=
MOLT-13 NHrac|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYCwVoE6UUN3ME2wMlAyPjN5IN88US=> MorwV2FPT0WU
LS-123 M1nGbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWO3Z4xWUUN3ME2wMlAyPjZ2IN88US=> MUPTRW5ITVJ?
NCI-SNU-5 Mlq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDVfpFYUUN3ME2wMlAyPzBzIN88US=> M3vxTnNCVkeHUh?=
Daudi M4TUUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTBTmFQUUN3ME2wMlAyPzB6IN88US=> NHj2fmZUSU6JRWK=
A253 MkeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDxToNSUUN3ME2wMlAyPzN6IN88US=> NFnwdGxUSU6JRWK=
TGBC1TKB NIeyfFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTBwMEG3OVIh|ryP M4PHO3NCVkeHUh?=
SJSA-1 NF75OFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\HV5FCUUN3ME2wMlAyPzZ5IN88US=> NV22O5d{W0GQR1XS
NCCIT M4D0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2T4U2lEPTB;MD6wNVc3QSEQvF2= NFj3ZW1USU6JRWK=
NCI-H69 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTBwMEG3O|gh|ryP NUDzO4dFW0GQR1XS
SH-4 Ml\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PxcGlEPTB;MD6wNVg6PSEQvF2= MYrTRW5ITVJ?
HCC1187 MoW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojZTWM2OD1yLkCxPVI1KM7:TR?= NYjyOFgzW0GQR1XS
HCC1599 MmHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVf1c5dMUUN3ME2wMlAzODJizszN MYHTRW5ITVJ?
ONS-76 NGnldFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPuToVKSzVyPUCuNFIxOzZizszN MmTBV2FPT0WU
KU812 Mof1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XGTmlEPTB;MD6wNlA{QSEQvF2= NGfUdGdUSU6JRWK=
ML-2 M1TBRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmr2TWM2OD1yLkCyNFQ4KM7:TR?= NFjZfWpUSU6JRWK=
HCE-T MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITQ[Y1KSzVyPUCuNFIxQTJizszN MYDTRW5ITVJ?
NCI-H446 NFmxNlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTBwMEKxNVIh|ryP M2jQdXNCVkeHUh?=
RPMI-6666 M1fzWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHtTWM2OD1yLkCyNVQ6KM7:TR?= MXjTRW5ITVJ?
MOLT-16 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHhTWM2OD1yLkCyNVU{KM7:TR?= MYHTRW5ITVJ?
JiyoyeP-2003 MlLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfXRWxtUUN3ME2wMlAzOTd4IN88US=> NG\NZppUSU6JRWK=
MHH-PREB-1 M3zFWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXV[|hvUUN3ME2wMlAzOTlzIN88US=> MkfsV2FPT0WU
MC-CAR NXvzVYNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTBwMEKzNlYh|ryP MUPTRW5ITVJ?
BC-3 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPSbXN3UUN3ME2wMlAzOzR2IN88US=> MXHTRW5ITVJ?
KINGS-1 MnPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTBwMEKzOVUh|ryP M1PEXXNCVkeHUh?=
PF-382 NE\hXIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPDPI1KSzVyPUCuNFI{PzhizszN NIPyRZBUSU6JRWK=
J-RT3-T3-5 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnQTWM2OD1yLkCyN|g{KM7:TR?= NFPtfGNUSU6JRWK=
SF539 M2jHdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUD5W2d3UUN3ME2wMlAzPDBzIN88US=> NYTlfGY1W0GQR1XS
LB831-BLC M{S5Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnxS|Q1UUN3ME2wMlAzPDh3IN88US=> M2\pNXNCVkeHUh?=
DMS-114 MoDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFz1VWpKSzVyPUCuNFI2ODJizszN NUXZfmJiW0GQR1XS
LB1047-RCC M1zVcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTBwMEK1NUDPxE1? MmPZV2FPT0WU
LB771-HNC M{LaUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTBwMEK1N|Qh|ryP NXHnVoxSW0GQR1XS
BB65-RCC M{PxV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTBwMEK1N|Qh|ryP MWTTRW5ITVJ?
BV-173 M{\CUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTBwMEK1OVQh|ryP Mkm0V2FPT0WU
ARH-77 M3vGVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTBwMEK2NFEh|ryP MWjTRW5ITVJ?
IST-MEL1 NITBeWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlq0TWM2OD1yLkCyOlI{KM7:TR?= MXfTRW5ITVJ?
NB1 M2HJd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkO0TWM2OD1yLkCyOlg4KM7:TR?= MYPTRW5ITVJ?
EoL-1-cell NEmwRpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jsO2lEPTB;MD6wNlY5QCEQvF2= M4\1dnNCVkeHUh?=
KY821 MmS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPDeHlKSzVyPUCuNFI3QTdizszN NE[0OINUSU6JRWK=
CMK NUe1[JhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGX5eW5KSzVyPUCuNFI4OzRizszN NGq0eGJUSU6JRWK=
NCI-H2126 MkLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;xe5lKSzVyPUCuNFI4PjhizszN M13sS3NCVkeHUh?=
NCI-H526 M{XKTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XGe2lEPTB;MD6wNlg6OSEQvF2= NFTRWmZUSU6JRWK=
COLO-684 NIPjVlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LYSGlEPTB;MD6wNlkxQCEQvF2= NVjuVWNIW0GQR1XS
NCI-H747 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTBwMEK5N|Mh|ryP M1jFT3NCVkeHUh?=
JAR NYm0XWdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvmdHlRUUN3ME2wMlAzQTR4IN88US=> MonDV2FPT0WU
MEG-01 NHX0NWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHoTWM2OD1yLkCyPVc5KM7:TR?= MnHXV2FPT0WU
MONO-MAC-6 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTBwMEOwNlMh|ryP M{PTUXNCVkeHUh?=
IST-SL1 MmrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XZfGlEPTB;MD6wN|A1OiEQvF2= NI\4V5pUSU6JRWK=
CPC-N NV\vTHJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInQeHNKSzVyPUCuNFMxPzlizszN NH3RVmlUSU6JRWK=
NCI-H1963 M2eyTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnJTWM2OD1yLkCzNVMyKM7:TR?= MmTLV2FPT0WU
K052 NIPTbW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPzT2E4UUN3ME2wMlA{OjR5IN88US=> NEHuWVVUSU6JRWK=
KM-H2 NHXRVI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVroWo9ZUUN3ME2wMlA{OzB5IN88US=> NGLYSWlUSU6JRWK=
TE-12 M2nxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTBwMEOzNFkh|ryP MWrTRW5ITVJ?
TK10 NGjyRXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFj5d49KSzVyPUCuNFM{PTZizszN NFfic29USU6JRWK=
NMC-G1 NXizUHFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Dzc2lEPTB;MD6wN|Q2OiEQvF2= NVvNd4NRW0GQR1XS
no-11 M2X1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1mwWGlEPTB;MD6wN|Q4QCEQvF2= Mke4V2FPT0WU
NCI-H524 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTBwMEO1Nlkh|ryP MYrTRW5ITVJ?
MHH-CALL-2 NYfQR3JmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvw[2NKSzVyPUCuNFM2PjJizszN Mkf1V2FPT0WU
GB-1 MlnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTBwMEO2JO69VQ>? MX;TRW5ITVJ?
OPM-2 NHvJTHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTBwMEO2O|Mh|ryP NU\uRWN7W0GQR1XS
RH-1 MnS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzBWYxmUUN3ME2wMlA{QDF7IN88US=> NG[2RmxUSU6JRWK=
NCI-H64 NWW0XYpHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTBwMEO4OVch|ryP NEPkUWVUSU6JRWK=
EVSA-T MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HNbGlEPTB;MD6wN|kzOyEQvF2= NX3UWmQzW0GQR1XS
KARPAS-299 M4TUfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvoTWM2OD1yLkCzPVgh|ryP MXrTRW5ITVJ?
MZ7-mel NXu1bZNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\XVnRNUUN3ME2wMlA1ODRizszN MmjLV2FPT0WU
LB373-MEL-D M3\wdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWO1UZJ3UUN3ME2wMlA1OTB3IN88US=> MoC4V2FPT0WU
HEL NVrIUHlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTBwMESxOEDPxE1? MXrTRW5ITVJ?
SW872 M324Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTBwMESyNUDPxE1? NFzqZ5ZUSU6JRWK=
DU-4475 M4C5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnBTWM2OD1yLkC0NlQ1KM7:TR?= M4G1fXNCVkeHUh?=
IST-SL2 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3NeYFKSzVyPUCuNFQzPzVizszN MoTGV2FPT0WU
NCI-H82 NGTYVXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTBwMESzNFch|ryP MmHXV2FPT0WU
LC4-1 NGHpRpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\PZppKSzVyPUCuNFQ{PTFizszN NGDsUnVUSU6JRWK=
HDLM-2 NXHGcJB1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDyTWM2OD1yLkC0N|kzKM7:TR?= MYPTRW5ITVJ?
MMAC-SF MlvJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE[5T5FKSzVyPUCuNFQ2OzRizszN MnrMV2FPT0WU
L-540 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTBwMES2N|kh|ryP NWnoXI5GW0GQR1XS
MZ2-MEL MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTBwMES3OFIh|ryP M4PEdXNCVkeHUh?=
LU-134-A NFPj[mZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTBwMES3O|Mh|ryP Ml;TV2FPT0WU
UACC-257 NU\OeI5UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVv4XZcyUUN3ME2wMlA1QDR7IN88US=> NXX6fZltW0GQR1XS
NCI-H1581 NHWxdVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfLVItWUUN3ME2wMlA1QTV|IN88US=> NHXUd5VUSU6JRWK=
NB17 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULvdo9UUUN3ME2wMlA1QTd7IN88US=> MU\TRW5ITVJ?
SBC-1 NF;yVpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7leJFRUUN3ME2wMlA2ODR{IN88US=> MmnVV2FPT0WU
TALL-1 NVLZboV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIj3NGxKSzVyPUCuNFUxPDVizszN M4C5cXNCVkeHUh?=
NCI-H1304 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTBwMEWyNFgh|ryP NIjqSHBUSU6JRWK=
NEC8 NUn3Z5dkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrETWM2OD1yLkC1Nlg3KM7:TR?= NVzQ[4EzW0GQR1XS
CAL-148 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TMPWlEPTB;MD6wOVQ{QSEQvF2= NWDjXIF[W0GQR1XS
CGTH-W-1 NXLrZm57T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2C1bWlEPTB;MD6wOVQ1QSEQvF2= NFOyfYNUSU6JRWK=
NCI-H889 NHHOVYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTBwMEW1PVIh|ryP NVLJXmFQW0GQR1XS
GR-ST MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTBwMEW2NlEh|ryP M4TqcnNCVkeHUh?=
KARPAS-422 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDlTWM2OD1yLkC1OlUh|ryP NIf4T21USU6JRWK=
RPMI-8866 NUXWU2JoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnLc4dKSzVyPUCuNFU4OTJizszN M{jLTXNCVkeHUh?=
SCLC-21H M3PnXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjJbnRoUUN3ME2wMlA2QDh2IN88US=> MXLTRW5ITVJ?
COR-L88 Ml7sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jNe2lEPTB;MD6wOVkzPyEQvF2= MnXyV2FPT0WU
LU-139 NVPJN|lrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTBwMEW5PFYh|ryP MoPjV2FPT0WU
SF126 M{DGWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELsNIhKSzVyPUCuNFYyOzNizszN NHvTcWhUSU6JRWK=
NCI-H1882 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\hTWM2OD1yLkC2OFI1KM7:TR?= NXnCVJJiW0GQR1XS
EW-24 NEPwW5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XCfGlEPTB;MD6wOlQ5OyEQvF2= Mn7hV2FPT0WU
CP67-MEL MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFeydlFKSzVyPUCuNFY5OSEQvF2= MVnTRW5ITVJ?
DG-75 MnzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTBwME[4PVkh|ryP NUPpdINXW0GQR1XS
LOXIMVI NXizbXk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjJemhKSzVyPUCuNFcxOjhizszN NUjaZ4ZDW0GQR1XS
HH MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGK1bplKSzVyPUCuNFcyPTdizszN MVXTRW5ITVJ?
K5 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3n0WmlEPTB;MD6wO|IzPiEQvF2= Ml7RV2FPT0WU
EC-GI-10 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILVcVNKSzVyPUCuNFczPTdizszN MkX0V2FPT0WU
SK-N-DZ NWfSOnZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfsTWM2OD1yLkC3N|A4KM7:TR?= Mly0V2FPT0WU
A3-KAW NES2dlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknUTWM2OD1yLkC3N|UyKM7:TR?= M4\i[HNCVkeHUh?=
MLMA MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHH2T4lKSzVyPUCuNFc1PjVizszN NEe4NI9USU6JRWK=
LB996-RCC NYm2bXJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfEbINOUUN3ME2wMlA4PzB5IN88US=> MX\TRW5ITVJ?
OS-RC-2 NH\XeZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\5c3ZnUUN3ME2wMlA4PzR6IN88US=> MYnTRW5ITVJ?
CTB-1 NX;EfVcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljWTWM2OD1yLkC3PFEh|ryP NGTXSGNUSU6JRWK=
IST-MES1 M4jtTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\ie2lEPTB;MD6wO|kyOiEQvF2= NIqwUWVUSU6JRWK=
LS-1034 Mk\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HBdWlEPTB;MD6wPFA{PSEQvF2= M4jCWHNCVkeHUh?=
HT NUS0dWlOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHsSI5FUUN3ME2wMlA5ODh4IN88US=> M1LZWXNCVkeHUh?=
NCI-H2141 M1vaWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PZcGlEPTB;MD6wPFEh|ryP NIXSOnNUSU6JRWK=
LB2518-MEL MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVm2TVZpUUN3ME2wMlA5OTRzIN88US=> NIPIdmdUSU6JRWK=
GI-ME-N Mme2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3SZ41KSzVyPUCuNFg1PTJizszN NHmxd3hUSU6JRWK=
TGW MnLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnjdIt1UUN3ME2wMlA5PjB5IN88US=> M3TTbnNCVkeHUh?=
SK-NEP-1 M3r0UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLnUXBKSzVyPUCuNFg3PDFizszN Ml3WV2FPT0WU
NOMO-1 NFy2OY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWCzXYRqUUN3ME2wMlA6Ojd3IN88US=> MX\TRW5ITVJ?
ES6 NVTBOG5sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fKeWlEPTB;MD6wPVU5QSEQvF2= NF\GbmdUSU6JRWK=
NCI-H209 NVvIdXZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTBwMEm3PFYh|ryP MVPTRW5ITVJ?
GAK MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnUTJJ[UUN3ME2wMlExOTZizszN MWHTRW5ITVJ?
BC-1 NEPteGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUC0TXdnUUN3ME2wMlExOzZzIN88US=> NFzzSlNUSU6JRWK=
KLE NIHC[m9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLQTWM2OD1yLkGwOFQ{KM7:TR?= MkThV2FPT0WU
EW-3 MlvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1uxSWlEPTB;MD6xNFk5KM7:TR?= MXPTRW5ITVJ?
NKM-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXOPJJKSzVyPUCuNVEyKM7:TR?= NHjuZ3VUSU6JRWK=
D-336MG MoLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7yTWM2OD1yLkGxNlQ1KM7:TR?= NF;6UJZUSU6JRWK=
NB69 M3PWTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYS0dIExUUN3ME2wMlEyOzBzIN88US=> NH3h[ZlUSU6JRWK=
D-263MG NEnGd45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTBwMUG3NVIh|ryP MnjFV2FPT0WU
KP-N-YS MnHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYniSGpFUUN3ME2wMlEzOjlzIN88US=> Mlz0V2FPT0WU
NCI-H1155 M{SwXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTBwMUK1OVgh|ryP NEjLfY1USU6JRWK=
BOKU NYTxR2J7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDnNFJKSzVyPUCuNVI2PzlizszN Mo\GV2FPT0WU
LAMA-84 M{jxOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HHe2lEPTB;MD6xNlk6KM7:TR?= NGmzcIxUSU6JRWK=
Raji MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;HTWM2OD1yLkGzNVE4KM7:TR?= MofyV2FPT0WU
LU-65 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPySG9KSzVyPUCuNVM{ODdizszN NWnFZ4xPW0GQR1XS
NCI-H187 NEiw[nZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTBwMUO5NlQh|ryP M1\McnNCVkeHUh?=
GCIY MlT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXnTWM2OD1yLkG0PVAyKM7:TR?= MmjpV2FPT0WU
NCI-H2107 NGLWfItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF6ybW5KSzVyPUCuNVUxQCEQvF2= M1fIPXNCVkeHUh?=
NCI-H1522 MkjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTBwMUWyOlYh|ryP MXrTRW5ITVJ?
NB6 MorCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\vOmlEPTB;MD6xOVYzOyEQvF2= NV34NYFSW0GQR1XS
EM-2 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTBwMUW3NFYh|ryP MmS1V2FPT0WU
HCC2218 MlHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLTcmJKSzVyPUCuNVU6QCEQvF2= NGLiV3BUSU6JRWK=
NCI-H748 M{fHOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fuOGlEPTB;MD6xOlM4PiEQvF2= NXrqNVN7W0GQR1XS
MS-1 MnXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzsTWM2OD1yLkG2OVM4KM7:TR?= M4i2SnNCVkeHUh?=
NB5 NVr3S4Z[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7JTWM2OD1yLkG2OVk4KM7:TR?= NWjKV4Z2W0GQR1XS
OMC-1 NGfs[XFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfMWWRUUUN3ME2wMlE3Pjh6IN88US=> MWrTRW5ITVJ?
NCI-H345 Mln5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoC3TWM2OD1yLkG2PVI5KM7:TR?= NFXLcFlUSU6JRWK=
L-428 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTBwMU[5OFUh|ryP NWCyZXp[W0GQR1XS
SCH M2DyUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTBwMUi2PFUh|ryP Mn7FV2FPT0WU
NCI-H1417 M2LVe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVf4V3B1UUN3ME2wMlE6OjJ5IN88US=> NF3hXWNUSU6JRWK=
COLO-320-HSR NUHwTWZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jzd2lEPTB;MD6xPVU{OiEQvF2= NX7HS5FMW0GQR1XS
BT-474 NUS0eXdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVThdXlNUUN3ME2wMlIxQDl{IN88US=> MnvuV2FPT0WU
GDM-1 NVvyNGVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI[5d4lKSzVyPUCuNlE6PzFizszN MX3TRW5ITVJ?
NCI-H2196 M1PXW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LMPGlEPTB;MD6yNlI{PSEQvF2= M4[4V3NCVkeHUh?=
KP-N-RT-BM-1 NWTKTZpDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTBwMkKzOFkh|ryP NWPXTYtoW0GQR1XS
KNS-81-FD MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWi0UoFjUUN3ME2wMlIzQTV6IN88US=> NXvXNJdyW0GQR1XS
COLO-668 MnjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mle0TWM2OD1yLkKzOlc2KM7:TR?= NFPyWXNUSU6JRWK=
C2BBe1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHXepBoUUN3ME2wMlI3PzR5IN88US=> NH72R3NUSU6JRWK=
Ramos-2G6-4C10 Mn3NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvqXJNiUUN3ME2wMlI3QTV2IN88US=> MknHV2FPT0WU
CAS-1 NIDNVotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MomyTWM2OD1yLkK3NFk3KM7:TR?= NY\lPHMyW0GQR1XS
GOTO Ml7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXqy[GRHUUN3ME2wMlI4QDl2IN88US=> NUmwWm5kW0GQR1XS
LP-1 NFnHW3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY[zVHZbUUN3ME2wMlI5ODV5IN88US=> MYrTRW5ITVJ?
NCI-SNU-1 M2HMUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDaTWM2OD1yLkK5OFIzKM7:TR?= MUPTRW5ITVJ?
EB-3 NYLQZmROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHQ[GtKSzVyPUCuNlk6PzlizszN NEHwb2xUSU6JRWK=
MHH-NB-11 Mo\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3:5eWlEPTB;MD6zNFQxOiEQvF2= M1vGbnNCVkeHUh?=
SK-N-FI NEnLfXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTBwM{G2PVIh|ryP NH3udVVUSU6JRWK=
HCC2157 MnXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HJVmlEPTB;MD6zN|kyOyEQvF2= NEC1XJZUSU6JRWK=
SIMA MnvNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zaOWlEPTB;MD6zOFU5OSEQvF2= MVXTRW5ITVJ?
MDA-MB-134-VI M3PWfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3vTWM2OD1yLkO2PVI5KM7:TR?= MYLTRW5ITVJ?
NCI-H1694 NGrIZmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml30TWM2OD1yLkO3JO69VQ>? MmXwV2FPT0WU
EHEB M2TzeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVn1Z3pTUUN3ME2wMlM6ODh3IN88US=> MXvTRW5ITVJ?
U-266 M2fZT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTDbVh{UUN3ME2wMlM6QDR4IN88US=> NYDNTGgxW0GQR1XS
LC-1F NVfsPYxzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHi1TmhKSzVyPUCuOFM4PjVizszN NFHmfnBUSU6JRWK=
SHP-77 Ml\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4WxbmlEPTB;MD60O|g2PSEQvF2= MljBV2FPT0WU
LS-513 NXz0b2Z6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3U[3BKSzVyPUCuOFk{ODdizszN NGfmOoRUSU6JRWK=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. [4]

お薦めの試験操作(参考用のみ)

細胞試験:

[1]

+ 展開
  • 細胞株: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
  • 濃度: 0.1-100 pM
  • 反応時間: 72 hours
  • 実験の流れ:

    Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.


    (参考用のみ)
動物試験:

[5]

+ 展開
  • 動物モデル: Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
  • 製剤: Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use.
  • 投薬量: 20 mg/kg
  • 投与方法: Administered via i.v.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 171 mg/mL (200.25 mM)
Ethanol 18 mg/mL (21.07 mM)
Water Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます:
5% DMSO+5% Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
2.5mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 853.91
化学式

C47H51NO14

CAS No. 33069-62-4
保管
別名 NSC 125973

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02181634 Active, not recruiting Cholangiocarcinoma PrECOG, LLC.|Celgene Corporation December 9, 2014 Phase 2
NCT03047265 Active, not recruiting Nasopharyngeal Carcinoma Sun Yat-sen University February 4, 2017 Phase 2
NCT02779855 Not yet recruiting Breast Cancer|Ductal Carcinoma|Invasive Breast Carcinoma|Invasive Ductal Breast Carcinoma H. Lee Moffitt Cancer Center and Research Institute|Amgen April 30, 2017 Phase 1|Phase 2
NCT00001426 Completed Ovarian Neoplasm National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 3, 1995 Phase 2
NCT01419548 Withdrawn Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 29, 2011 Phase 1
NCT01051934 Completed Non-Small Cell Lung Cancer|Adenocarcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) December 29, 2009 Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    I am interested in the product S1150 for in vivo studies, could you please give some suggestions for the formulation?

  • 回答:

    S1150 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension. If the you want to inject it, there is another vehicle, 5% DMSO+5% Tween 80+ddH2O. S1150 can dissolve in it at 2.5mg/ml as a clear solution. It is a common formulation we used, but is not cited from reference.

  • 質問2:

    the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?

  • 回答:

    Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

Microtubule Associatedシグナル伝達経路

相関Microtubule Associated製品

Tags: Paclitaxelを買う | Paclitaxel ic50 | Paclitaxel供給者 | Paclitaxelを購入する | Paclitaxel費用 | Paclitaxel生産者 | オーダーPaclitaxel | Paclitaxel化学構造 | Paclitaxel分子量 | Paclitaxel代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID